FivePrime Therapeutics, Inc. Nabs $495M Deal With Human Genome Sciences, Inc. to Develop Cancer Drug

Published: Mar 17, 2011

ROCKVILLE, Md. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime’s FP-1039 product for multiple cancers. FP-1039 is a first-in-class biologic discovered by FivePrime that targets multiple fibroblast growth factor (FGF) ligands. Under the terms of the agreement, HGS has acquired rights to develop and commercialize FP-1039 in the United States, Canada and the EU markets, while FivePrime retains minority co-promotion rights in the U.S. and full development and commercialization rights in rest of world territories, including Asia.

Back to news